PT - JOURNAL ARTICLE AU - Yedavalli, Vivek AU - Koneru, Manisha AU - Hoseinyazdi, Meisam AU - Greene, Cynthia AU - Copeland, Karen AU - Xu, Risheng AU - Luna, Licia AU - Caplan, Justin AU - Dmytriw, Adam AU - Guenego, Adrien AU - Heit, Jeremy AU - Albers, Gregory AU - Wintermark, Max AU - Gonzalez, Fernando AU - Urrutia, Victor AU - Huang, Judy AU - Leigh, Richard AU - Marsh, Elisabeth AU - Llinas, Rafael AU - Hillis, Argye AU - Nael, Kambiz TI - Pretreatment and interventional parameters predict excellent recanalization of large vessel occlusion in patients with acute ischemic stroke AID - 10.1101/2023.08.22.23294452 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.22.23294452 4099 - http://medrxiv.org/content/early/2023/08/24/2023.08.22.23294452.short 4100 - http://medrxiv.org/content/early/2023/08/24/2023.08.22.23294452.full AB - Background In patients with acute ischemic stroke secondary to large vessel occlusion (AIS-LVO), improved functional outcomes have been reported in patients who achieve Modified Thrombolysis In Cerebral Infarction (mTICI) 2c/3 (excellent recanalization) over mTICI 2b. We aimed to determine pretreatment and interventional variables that could predict achieving mTICI 2c/3 over 2b reperfusion in patients who underwent technically successful mechanical thrombectomy (MT).Methods In this retrospective study, consecutive AIS patients with anterior circulation LVO who underwent MT and achieved recanalization with mTICI 2b/2c/3 were included. We evaluated the association between pretreatment clinical and imaging variables and interventional parameters in patients who achieved mTICI 2c/3 vs. 2b using logistic regression and ROC analyses.Results From 5/11/2019 to 10/09/2022, 149 consecutive patients met our inclusion criteria (median 70 years old [IQR 65 - 78.5], 57.7% female). Adjusted multivariate regression analyses showed that patients with excellent recanalization had lower admission NIHSS (aOR 0.93, p = 0.036), were less likely to have a history of diabetes mellitus (DM) (aOR 0.42, p = 0.050) and prior stroke (aOR 0.27, p = 0.007), had a cerebral blood volume (CBV) index >= 0.7 (aOR 3.75, p = 0.007), and were more likely to achieve excellent recanalization with aspiration alone (aOR 2.89, p = 0.012). A multivariate logistic regression model comprising these independent factors predicted mTICI 2c/3 with an AUC 0.79 (95% CI: 0.68-0.86; p < 0.001), sensitivity of 94%; specificity of 41%.Conclusion Robust collateral status (CS) defined by CBV index >= 0.7, absence of DM and prior stroke, lower initial stroke severity, and direct aspiration are all predictive of excellent recanalization in successfully recanalized AIS-LVO patients. Our findings highlight the prognostic implications of robust CS, DM and stroke prevention, as well as use of aspiration alone in maximizing the likelihood of excellent recanalization.Competing Interest StatementDrs. Greg Albers, Jeremy Heit, and Vivek Yedavalli are consultants for Rapid (iSchemaView, Menlo Park, CA); all other authors do not have any personal or financial disclosures.Funding StatementNo funding sources to support this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:JHU-IRB00269637I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData can be made available upon reasonable request.